Scleroderma Newsroom
ISN News Manager: Jo Frowde
Media Stories
Scleroderma Archive
2017: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2018 - 2017 - 2016 - 2015

October 2017 Scleroderma News

Emerald Health Pharmaceuticals Granted FDA Orphan Drug Designation for Systemic Scleroderma. Emerald Health Pharmaceuticals Inc. (EHP), which is developing medications based on cannabinoid science, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its lead molecule, EHP-101, for the treatment of systemic scleroderma. Globe Newswire, 10/20/2017. (Also see Endocannabinoid System)

The critical need for accurately defining digital ulcers in scleroderma. The high unmet need for a standardized method of defining digital ulcers is a major challenge not only for treatment, but also for development of new therapies. Journal of Scleroderma and Related Disorders, JSRD 2017; 2(2): 69 - 71. (Also see Digital Ulcers)

Managing systemic sclerosis-related interstitial lung disease (SSC–ILD) in the modern treatment era. This review describes the current and experimental therapies available and also explores unanswered questions directly relevant to patient care and future research efforts for SSc–ILD. Journal of Scleroderma and Related Disorders, JSRD 2017; 2(2): 72 - 83. (Also see Treatments for Pulmonary Fibrosis)

Controversies on the use of steroids in systemic sclerosis. This review focuses on the main area of controversy, that is whether corticosteroids should be prescribed in patients with early diffuse cutaneous SSc (dcSSc). Journal of Scleroderma and Related Disorders, JSRD 2017; 2(2): 84 - 91. (Also see Glucocorticoids, Steroids (Prednisone) Warnings for Scleroderma)

Complex pathophysiology of pulmonary hypertension (PAH) associated with systemic sclerosis (SSc): potential unfavorable effects of vasodilators. Pre–assessment of pathophysiology of pulmonary hypertension and cautious monitoring during the treatment are necessary to achieve better outcomes in patients with SSc–PAH. Journal of Scleroderma and Related Disorders, JSRD 2017; 2(2): 92 - 99. (Also see Treatments for Pulmonary Arterial Hypertension: PDE-5 Inhibitors)

Association between objective signs and subjective symptoms of dry eye disease in patients with systemic sclerosis. A significant correlation was found between the Ocular Surface Disease Index (OSDI) as a subjective parameter and disease duration. PubMed, Rheumatol Int, 09/07/2017. (Also see Sjögren's Syndrome)

CCL2 in the Circulation Predicts Long-Term Progression of Interstitial Lung Disease (ILD) in Patients With Early Systemic Sclerosis (SSc). Higher CCL2 levels in the circulation were predictive of ILD progression and poorer survival in patients with early SSc, which support the notion that CCL2 has a role as a biomarker and potential therapeutic target. PubMed, Arthritis Rheumatol, 2017 Sep;69(9):1871-1878. (Also see Pulmonary Fibrosis)

Spectrum of esophageal dysmotility in systemic sclerosis on high–resolution esophageal manometry as defined by Chicago classification. The severity of gastroesophageal reflux disease related endoscopic findings correlated with the degree of esophageal dysmotility on high–resolution esophageal manometry. PubMed, Dis Esophagus, 2017 Dec 1;30(12):1-6. (Also see Dysmotility Syndrome)

Diagnosing and managing scleroderma–related pulmonary arterial hypertension. This article describes scleroderma–related PAH and its diagnosis and management. PubMed, JAAPA, 2017 Sep;30(9):11-18. (Also see Pulmonary Hypertension Diagnosis)

Systematic review and meta–analysis of the epidemiology of polyautoimmunity in Sjögren's syndrome (secondary Sjögren's syndrome (sSS)) focusing on autoimmune rheumatic diseases. Prevalence rates of sSS vary widely in different populations and the results of this meta–analysis highlight the need for better quality population studies. PubMed, Scand J Rheumatol, 2017 Sep 20:1-14. (Also see Sjögren's Syndrome)

Cancers associated with systemic sclerosis (SSc) involving anti-RNA polymerase III antibodies. Anti-RNA polymerase III antibodies are useful for SSc diagnosis in patients without anti-centromere or anti-Scl70 antibodies and their presence must lead physicians to screen for associated cancer, even in the absence of clinical signs. PubMed, Ann Dermatol Venereol, 09/13/2017. (Also see Antibodies and Cancer)

Go to Scleroderma Medical News: September 2017

Giving Assistant
United Way of Central New Mexico
United Way of Snohomish County
See ISN News for recent donors, including Pam Hop, Margaret Roof, Winifred Schillberg, Arnold Slotkin, and Juliet Youkhana. Plus donations in honor of Kim Thwaits, and in loving memory of Marta Marx, Jim Miller, and Arlene Marie Petulla.
Click Here to Donate or Shop
or click on the floating green DONATE button.


TOLL FREE HOTLINE, U.S. and Canada: 1-800-564-7099
Ask for our Free Info Packet by email or postal mail!

SCLERO.ORG is the world leader for trustworthy research, support, education and awareness for scleroderma and related illnesses, such as pulmonary hypertension. We are a service of the nonprofit International Scleroderma Network (ISN), which is a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team, or Volunteer. Donations may also be mailed to:

International Scleroderma Network (ISN)
7455 France Ave So #266
Edina, MN 55435-4702 USA
Email [email protected] to request our Welcome email, or to report bad links or to update this page content. Privacy Policy.

The most important thing in the world to know about scleroderma is!

Donate Now
Copyright 1998-2018, International Scleroderma Network. AKA Scleroderma from A to Z and SCLERO.ORG. All Rights Reserved.